C3 Glomerulopathy: From Early Recognition to Individualized Targeted Therapy
Annenberg Center for Health Sciences
- 5
- Episodes
- Bi-weekly
- Cadence
- 2026
- First episode
About C3 Glomerulopathy: From Early Recognition to Individualized Targeted Therapy
The emergence of novel targeted complement inhibitors has created new opportunities to improve the health outcomes for patients with C3 glomerulopathy (C3G). Andrew Bomback, MD, MPH, discusses the contemporary management of patients with C3G, highlighting the disease burden and complement pathway dysregulation. The safety and efficacy of approved targeted complement inhibitors are reviewed, including the importance of long-term monitoring and associated vaccination strategies. Dr. Bomback also shares his thoughts about providing personalized care by an interprofessional care team.
- Publisher
- Annenberg Center for Health Sciences
- Category
- health & fitness
- Language
- en
- Explicit
- No
- First episode
- 29 Aug 2026
- Latest episode
- 29 Aug 2026
Latest episodes
5 episodes in the feed.
29 Aug 2026
Optimizing Care
29 Aug 2026
Targeted Treatments
29 Aug 2026
Diagnosis
29 Aug 2026
Pathogenesis
29 Aug 2026
Burden of Disease
Host of C3 Glomerulopathy: From Early Recognition to Individualized Targeted Therapy?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.